Baxter acquires $900m oncology portfolio for spin-out-in-waiting

Baxter has bolstered the oncology offering of its soon to be spun out BioScience unit – Baxalta – through the acquisition of the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria of Italy for $900m.